About 16 results found for searched term "TA-02" (0.051 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1813 | PCI-24781 | HDAC |
| Abexinostat; CRA-024781 | ||
| PCI-24781 is a novel and potent histone deacetylase (HDAC) inhibitor with IC50 value of 0.43 to 2.7 μM. *The compound is unstable in solutions, freshly prepared is recommended | ||
| M1871 | Roflumilast | PDE |
| APTA-2217; BYK 20869; B9302-107 | ||
| Roflumilast (APTA-2217; BYK 20869; B9302-107) is a novel and selective, long-acting inhibitor of phosphodiesterase 4 (PDE-4). | ||
| M2432 | Bardoxolone Methyl | IκB/IKK |
| RTA 402, TP-155, NSC 713200,CDDO Methyl ester | ||
| Bardoxolone Methyl is an IKK inhibitor with potent pro-apoptotic and anti-inflammatory activities, as well as an activator of the Nrf2 pathway and an inhibitor of the NF-κB pathway. | ||
| M4868 | Domatinostat (4SC-202) | HDAC |
| 4SC-202 | ||
| Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). | ||
| M6146 | TA-02 | p38 MAPK |
| TA 02; TA02 | ||
| TA-02 is a p38 MAPK inhibitor with IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. | ||
| M9020 | TAS-102 | DNA/RNA Synthesis |
| Trifluridine/Tipiracil HCl; Trifluridine-tipiracil hydrochloride mixture | ||
| TAS-102 is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. | ||
| M9332 | Apilimod | Others |
| STA-5326; LAM-002A free base; AIT-101 | ||
| Apilimod is a potent IL-12/IL-23 inhibitor, and it is also a cell permeable small molecule which specifically inhibits PIKfyve with an IC50 of 14 nM in an in vitro kinase assay. | ||
| M9647 | Orludodstat (BAY-2402234) | DHODH |
| BAY-2402234 is a potent and selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment of myeloid malignancies, with an IC50 of 1.2 nM. | ||
| M10279 | Ibiglustat | Glucosylceramide Synthase |
| Venglustat; SAR402671; GZ402671 | ||
| Ibiglustat (Venglustat) is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor. | ||
| M10434 | Olutasidenib (FT-2102) | Isocitrate Dehydrogenase (IDH) |
| FT-2102 | ||
| Olutasidenib (FT-2102) is a highly potent and selective, orally active, brain penetrant mutant Isocitrate dehydrogenase 1 (IDH1) inhibitor, with IC50 values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively. | ||
| M13688 | Soblidotin | Microtubule |
| Auristatin PE; TZT-1027 | ||
| Soblidotin (Auristatin PE) is a novel synthetic Dolastatin 10 derivative and inhibitor of tubulin polymerization. | ||
| M14716 | Ibiglustat (L-Malic acid) | Glucosylceramide Synthase |
| Venglustat (L-Malic acid); SAR402671 (L-Malic acid); GZ402671 (L-Malic acid) | ||
| Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. | ||
| M20689 | Sparsentan (RE-021) | Endothelin Receptor |
| PS-433540; RE-021; DARA-a; BMS-346567 | ||
| Sparsentan (PS-433540, RE-021, DARA) is a first-in-class, orally active, high-affinity dual antagonist of the endothelin type A receptor (ETA) and Angiotensin II type 1 (AT1) receptor, with Ki values of 9.3 and 0.8 nM, respectively. | ||
| M21189 | TAK-020 | BTK |
| TAK-020 is a highly selective oral covalent BTK inhibitor with a promising safety and tolerability profile for both hematologic malignancies and autoimmune diseases. | ||
| M25429 | Rezafungin acetate | Anti-infection |
| Biafungin acetate; CD101 acetate; SP-3025 acetate | ||
| Rezafungin acetate is a novel echinocandin-based antifungal agent with potent antifungal activity against Candida, Aspergillus and Pneumocystis. | ||
| M52399 | Tau Peptide (74-102) (Exon 3/Insert 2 Domain) | Tau Protein |
| Tau Peptide (74-102) (Exon 3/Insert 2 Domain) is aTau fragment. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
